Danaher Corporation (DHR)
- Previous Close
250.41 - Open
249.93 - Bid --
- Ask --
- Day's Range
245.28 - 250.64 - 52 Week Range
182.09 - 259.00 - Volume
2,854,560 - Avg. Volume
2,712,150 - Market Cap (intraday)
182.061B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
45.02 - EPS (TTM)
5.46 - Earnings Date Jul 23, 2024 - Jul 29, 2024
- Forward Dividend & Yield 1.08 (0.44%)
- Ex-Dividend Date Mar 27, 2024
- 1y Target Est
252.85
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
www.danaher.com61,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DHR
Performance Overview: DHR
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DHR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DHR
Valuation Measures
Market Cap
182.06B
Enterprise Value
193.19B
Trailing P/E
45.10
Forward P/E
32.79
PEG Ratio (5yr expected)
2.93
Price/Sales (ttm)
7.72
Price/Book (mrq)
3.41
Enterprise Value/Revenue
8.14
Enterprise Value/EBITDA
26.49
Financial Highlights
Profitability and Income Statement
Profit Margin
18.55%
Return on Assets (ttm)
3.86%
Return on Equity (ttm)
7.76%
Revenue (ttm)
23.74B
Net Income Avi to Common (ttm)
4.07B
Diluted EPS (ttm)
5.46
Balance Sheet and Cash Flow
Total Cash (mrq)
7.03B
Total Debt/Equity (mrq)
36.04%
Levered Free Cash Flow (ttm)
4.86B
Research Analysis: DHR
Company Insights: DHR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: DHR
Analyst Report: Danaher Corporation
In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
RatingPrice TargetWeekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
Analyst Report: Danaher Corp.
Danaher is a diversified life sciences and diagnostics company with global operations. In March 2020, it acquired the GE Biopharma business and renamed it Cytiva. Danaher has continued to make acquisitions, including Aldevron in 2021 and the pending acquisition of Abcam, that strengthen its technology and manufacturing capabilities.
RatingPrice TargetMarket Update: DHR, QSR, ANET
Stocks bounced back on Wednesday from yesterday's inflation fueled sell-off. Chicago Fed President Goolsbee noted that 'Even if inflation comes in a bit higher for a few months...it would still be consistent with our path back to target.' The Dow was up 0.1%, the S&P rose 0.4%, and the Nasdaq gained 0.7%. Crude oil fell slightly to $77.50 per barrel, while gold fell $2 to $2005 per ounce.